Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
- PMID: 27624958
- PMCID: PMC5146720
- DOI: 10.1093/cid/ciw636
Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections
Abstract
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
Keywords: Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
Comment in
-
Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat".Clin Infect Dis. 2016 Dec 15;63(12):1619-1621. doi: 10.1093/cid/ciw639. Epub 2016 Sep 13. Clin Infect Dis. 2016. PMID: 27624957 Free PMC article. No abstract available.
Similar articles
-
Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.Clin Infect Dis. 2018 Jan 6;66(2):163-171. doi: 10.1093/cid/cix783. Clin Infect Dis. 2018. PMID: 29020404 Free PMC article.
-
Treating complicated carbapenem-resistant enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation.Int J Antimicrob Agents. 2017 Jun;49(6):770-773. doi: 10.1016/j.ijantimicag.2017.01.018. Epub 2017 Apr 4. Int J Antimicrob Agents. 2017. PMID: 28389354
-
Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections.Antimicrob Agents Chemother. 2017 Jun 27;61(7):e00449-17. doi: 10.1128/AAC.00449-17. Print 2017 Jul. Antimicrob Agents Chemother. 2017. PMID: 28483952 Free PMC article.
-
The β-Lactams Strike Back: Ceftazidime-Avibactam.Pharmacotherapy. 2015 Aug;35(8):755-70. doi: 10.1002/phar.1622. Pharmacotherapy. 2015. PMID: 26289307 Free PMC article. Review.
-
Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.Expert Opin Pharmacother. 2016 Dec;17(17):2341-2349. doi: 10.1080/14656566.2016.1249847. Epub 2016 Oct 31. Expert Opin Pharmacother. 2016. PMID: 27758148 Review.
Cited by
-
Ceftazidime-avibactam induced renal disorders: past and present.Front Pharmacol. 2024 Jan 22;15:1329307. doi: 10.3389/fphar.2024.1329307. eCollection 2024. Front Pharmacol. 2024. PMID: 38318141 Free PMC article. Review.
-
Enhancing the activity of β-lactamase inhibitory protein-II with cell-penetrating peptide against KPC-2-carrying Klebsiella pneumoniae.PLoS One. 2024 Jan 26;19(1):e0296727. doi: 10.1371/journal.pone.0296727. eCollection 2024. PLoS One. 2024. PMID: 38277388 Free PMC article.
-
The Klebsiella pneumoniae carbapenemase (KPC) β-Lactamase Has Evolved in Response to Ceftazidime Avibactam.Antibiotics (Basel). 2023 Dec 31;13(1):40. doi: 10.3390/antibiotics13010040. Antibiotics (Basel). 2023. PMID: 38247599 Free PMC article.
-
Comparison of the inoculum effect of in vitro antibacterial activity of Imipenem/relebactam and Ceftazidime/avibactam against ESBL-, KPC- and AmpC-producing Escherichia coli and Klebsiella pneumoniae.Ann Clin Microbiol Antimicrob. 2023 Dec 10;22(1):107. doi: 10.1186/s12941-023-00660-5. Ann Clin Microbiol Antimicrob. 2023. PMID: 38072972 Free PMC article.
-
Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance.Antibiotics (Basel). 2023 Nov 10;12(11):1612. doi: 10.3390/antibiotics12111612. Antibiotics (Basel). 2023. PMID: 37998814 Free PMC article. Review.
References
-
- Acycaz (Ceftazidime-avibactam). Prescribing information. Cincinnati, Ohio: Forest Pharmaceuticals, Inc, 2016.
-
- Shields RK, Clancy CJ, Hao B et al. . Effects of Klebsiella pneumoniae carbapenemase subtypes, extended-spectrum beta-lactamases and porin mutations on the in vitro activity of ceftazidime-avibactam against carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 59:5793–7. - PMC - PubMed
-
- Center for Disease Control and Prevention. Healthcare-associated infections (HAIs): CRE definition. Available at: https://www.cdc.gov/hai/organisms/cre/definition.html. Accessed 6 April 2016.
-
- Centers for Disease Control and Prevention/National Healthcare Safety Network Surveillance Definitions for Specific Types of Infections (January 2016). Available at: http://www.cdc.gov/nhsn/PDFs/pscManual/17pscNosInfDef_current.pdf Accessed 1 March.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
